Renquan Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Renquan Zhang has a total of 100 co-authors. Here are the top co-authors by number of shared publications:
Kaiming Wu
First Affiliated Hospital of Anhui Medical University
3 shared publicationsLong Yao
First Affiliated Hospital of Anhui Medical University
3 shared publicationsYan Dang
Department of Thoracic Surgery, the First Affiliated Hospital of Anhui Medical University, Hefei, PR China
3 shared publicationsChen Lu
Department of Thoracic Surgery, the First Affiliated Hospital of Anhui Medical University, China
2 shared publicationsFeng Xu
Department of Thoracic Surgery, the First Affiliated Hospital of Anhui Medical University, China
2 shared publicationsHuaguang Pan
First Affiliated Hospital of Anhui Medical University
2 shared publications
Latest Publications
- Open Access
- 19 August 2026
- Published by Springer Nature in Research Square
Neoadjuvant camrelizumab plus chemotherapy versus chemotherapy alone for resectable esophageal squamous cell carcinoma: A Prospective Multicenter randomised controlled study
Background: Camrelizumab combined with chemotherapy has a very ideal therapeutic effect and low toxicity in the treatment of solid tumors. Camrelizumab plays an important role in the treatment of locally advanced esophageal squamouscell carcinoma. Methods: This study is a prospective, multicenter, randomised controlled study. Inclusion criteria were patients aged 18-75 years who had not received other treatments previously and had histologically confirmed resectable locally advanced esophageal squamous cell carcinoma (clinical stages cT1-4N1-3M0 and cT3-4N0M0). Random 1:1, patients received camrelizumab combined with chemotherapy (experimental group) or chemotherapy alone (control group). Results: From January 2021 to December 2024, 248 patients from four centers were enrolled. In the experimental group and the control group, 3 patients and 21 patients respectively did not receive surgical treatment. The surgical approach mainly involved endoscopic surgery. The R0 resection rate in the experimental group was 98.3%, the pathological complete response (pCR) rate was 20.7%, and the major pathological response (MPR) rate was 31.4%. In the control group, the R0 resection rate was 97.1%, the pCR rate was 11.5%, and the MPR rate was 20.2%. The median Event-free survival (EFS) was 32 months VS 20 months. Overall, the adverse reactions were mainly of grade 1-2. The incidence of grade 3 or higher adverse events was low in both groups (0.8% in the experimental group vs. 2.4% in the control group), and no grade 4 adverse events occurred in the experimental group. Conclusions: Research data shows that camrelizumab combined with chemotherapy has a definite efficacy and controllable safety in the neoadjuvant treatment of esophageal squamous cell carcinoma. Follow-up will be conducted to analyze the research data results and their correlation with the efficacy. Trial registration: Chinese Clinical Trial Registry (ChiCTR) ChiCTR2000040330. Registered on November 28, 2020. https://www.chictr.org.cn/showproj.html?proj=64767 This study adheres to the CONSORT 2025 guidelines for reporting randomized controlled trials.
- 19 August 2026
- Published by Springer Nature in Research Square
Open AccessNeoadjuvant camrelizumab plus chemotherapy versus chemotherapy alone for resectable esophageal squamous cell carcinoma: A Prospective Multicenter randomised controlled study
Background: Camrelizumab combined with chemotherapy has a very ideal therapeutic effect and low toxicity in the treatment of solid tumors. Camrelizumab plays an important role in the treatment of locally advanced esophageal squamouscell carcinoma. Methods: This study is a prospective, multicenter, randomised controlled study. Inclusion criteria were patients aged 18-75 years who had not received other treatments previously and had histologically confirmed resectable locally advanced esophageal squamous cell carcinoma (clinical stages cT1-4N1-3M0 and cT3-4N0M0). Random 1:1, patients received camrelizumab combined with chemotherapy (experimental group) or chemotherapy alone (control group). Results: From January 2021 to December 2024, 248 patients from four centers were enrolled. In the experimental group and the control group, 3 patients and 21 patients respectively did not receive surgical treatment. The surgical approach mainly involved endoscopic surgery. The R0 resection rate in the experimental group was 98.3%, the pathological complete response (pCR) rate was 20.7%, and the major pathological response (MPR) rate was 31.4%. In the control group, the R0 resection rate was 97.1%, the pCR rate was 11.5%, and the MPR rate was 20.2%. The median Event-free survival (EFS) was 32 months VS 20 months. Overall, the adverse reactions were mainly of grade 1-2. The incidence of grade 3 or higher adverse events was low in both groups (0.8% in the experimental group vs. 2.4% in the control group), and no grade 4 adverse events occurred in the experimental group. Conclusions: Research data shows that camrelizumab combined with chemotherapy has a definite efficacy and controllable safety in the neoadjuvant treatment of esophageal squamous cell carcinoma. Follow-up will be conducted to analyze the research data results and their correlation with the efficacy. Trial registration: Chinese Clinical Trial Registry (ChiCTR) ChiCTR2000040330. Registered on November 28, 2020. https://www.chictr.org.cn/showproj.html?proj=64767 This study adheres to the CONSORT 2025 guidelines for reporting randomized controlled trials.
- 18 March 2026
- Published by Elsevier in Food Chemistry
- Vol. 512, 148913
Impact of sonication and sodium chloride on the interaction and gelation behavior of soy protein isolate/κ-carrageenan mixtures
- 18 March 2026
- Published by Elsevier in Food Chemistry
- Vol. 512, 148913
Impact of sonication and sodium chloride on the interaction and gelation behavior of soy protein isolate/κ-carrageenan mixtures
- Open Access
- 19 June 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1610721
SNRPB2 facilitates esophageal squamous cell carcinoma oncogenesis and progression via E2F4 stabilization
Introduction: Esophageal cancer (ESCA) is a highly aggressive malignancy with poor prognosis. Small nuclear ribonucleoprotein polypeptide B2 (SNRPB2) is a core component of the spliceosome involved in pre-mRNA splicing. However, its role in tumor development and progression remains largely unclear. This study aimed to evaluate the clinical relevance and prognostic value of SNRPB2 in ESCA.Methods: SNRPB2 mRNA expression and genetic alterations were analyzed using GEPIA2 and cBioPortal. Protein expression was assessed by immunohistochemistry in paraffin-embedded esophageal squamous cell carcinoma (ESCC) tissues. Functional assays in ESCC cell lines were conducted to determine the biological role of SNRPB2. Immune-related and functional analyses were performed using TIMER, TISIDB, TISCH, Gene Ontology (GO), and Gene Set Enrichment Analysis (GSEA). Cycloheximide (CHX) chase assays were used to assess protein stability.Results: SNRPB2 mRNA was upregulated in ESCA and associated with tumor progression and poor prognosis. Immunohistochemistry confirmed high SNRPB2 protein expression in ESCC, correlating with vessel carcinoma embolus, lymph node metastasis, clinical stage, and tumor grade. SNRPB2 knockdown significantly inhibited ESCC cell proliferation, migration, and invasion in vitro and in vivo. GSEA indicated that SNRPB2 suppresses the Rb/E2F pathway. Mechanistically, SNRPB2 stabilized E2F4 protein by preventing its proteasomal degradation, and E2F4 overexpression reversed the tumor-suppressive effects of SNRPB2 silencing. Immune analyses showed that SNRPB2 expression correlated with increased infiltration of activated CD8+ T cells, γδ T cells, dendritic cells, and monocytes, as well as immune-related genes including PDCD1, CD274, CTLA4, HLA-DRA, and B2M. These findings suggest a dual role for SNRPB2 in promoting tumor progression and modulating the immune microenvironment in ESCA.Conclusion: SNRPB2 promotes ESCC progression by stabilizing E2F4 and regulating cell cycle genes. It is also associated with immune infiltration and gene expression in ESCA. SNRPB2 may serve as a prognostic biomarker and potential therapeutic target in esophageal cancer.
- 19 June 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1610721
Open AccessSNRPB2 facilitates esophageal squamous cell carcinoma oncogenesis and progression via E2F4 stabilization
Introduction: Esophageal cancer (ESCA) is a highly aggressive malignancy with poor prognosis. Small nuclear ribonucleoprotein polypeptide B2 (SNRPB2) is a core component of the spliceosome involved in pre-mRNA splicing. However, its role in tumor development and progression remains largely unclear. This study aimed to evaluate the clinical relevance and prognostic value of SNRPB2 in ESCA.Methods: SNRPB2 mRNA expression and genetic alterations were analyzed using GEPIA2 and cBioPortal. Protein expression was assessed by immunohistochemistry in paraffin-embedded esophageal squamous cell carcinoma (ESCC) tissues. Functional assays in ESCC cell lines were conducted to determine the biological role of SNRPB2. Immune-related and functional analyses were performed using TIMER, TISIDB, TISCH, Gene Ontology (GO), and Gene Set Enrichment Analysis (GSEA). Cycloheximide (CHX) chase assays were used to assess protein stability.Results: SNRPB2 mRNA was upregulated in ESCA and associated with tumor progression and poor prognosis. Immunohistochemistry confirmed high SNRPB2 protein expression in ESCC, correlating with vessel carcinoma embolus, lymph node metastasis, clinical stage, and tumor grade. SNRPB2 knockdown significantly inhibited ESCC cell proliferation, migration, and invasion in vitro and in vivo. GSEA indicated that SNRPB2 suppresses the Rb/E2F pathway. Mechanistically, SNRPB2 stabilized E2F4 protein by preventing its proteasomal degradation, and E2F4 overexpression reversed the tumor-suppressive effects of SNRPB2 silencing. Immune analyses showed that SNRPB2 expression correlated with increased infiltration of activated CD8+ T cells, γδ T cells, dendritic cells, and monocytes, as well as immune-related genes including PDCD1, CD274, CTLA4, HLA-DRA, and B2M. These findings suggest a dual role for SNRPB2 in promoting tumor progression and modulating the immune microenvironment in ESCA.Conclusion: SNRPB2 promotes ESCC progression by stabilizing E2F4 and regulating cell cycle genes. It is also associated with immune infiltration and gene expression in ESCA. SNRPB2 may serve as a prognostic biomarker and potential therapeutic target in esophageal cancer.
- Open Access
- 9 January 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1484234
Integrated single-cell RNA sequencing reveals the tumor heterogeneity and microenvironment landscape during liver metastasis in adenocarcinoma of esophagogastric junction
Background: Adenocarcinoma of the esophagogastric junction (AEGJ) is a highly aggressive tumor that frequently metastasizes to the liver. Understanding the cellular and molecular mechanisms that drive this process is essential for developing effective therapies.Methods: We employed single-cell RNA sequencing to analyze the tumor heterogeneity and microenvironmental landscape in patients with AEGJ liver metastases. This approach enabled us to characterize the diverse cell populations involved in the liver metastatic process.Results: Our analysis revealed a significant involvement of fibroblasts and mural cells in AEGJ liver metastasis. We identified a specific fibroblast type in AEGJ liver metastasis and observed distinct gene expression patterns between adenocarcinoma of the esophagogastric junction and other stomach adenocarcinomas. Our study demonstrated high expression of the SFRP2 gene in pericyte cells during the liver metastasis of AEGJ. The incorporation of GEO, TCGA, and immunofluorescence staining of SFRP2 expression enhanced our study. High expression of SFRP2 in pericytes may influence vascular stability and angiogenesis through the Wnt pathway.Conclusion: Our study provides novel insights into the cellular interactions and molecular mechanisms that underlie AEGJ liver metastasis. Targeting the identified subtype of fibroblasts or influencing SFRP2 gene expression in pericytes may offer new therapeutic strategies for combating this aggressive tumor.
- 9 January 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1484234
Open AccessIntegrated single-cell RNA sequencing reveals the tumor heterogeneity and microenvironment landscape during liver metastasis in adenocarcinoma of esophagogastric junction
Background: Adenocarcinoma of the esophagogastric junction (AEGJ) is a highly aggressive tumor that frequently metastasizes to the liver. Understanding the cellular and molecular mechanisms that drive this process is essential for developing effective therapies.Methods: We employed single-cell RNA sequencing to analyze the tumor heterogeneity and microenvironmental landscape in patients with AEGJ liver metastases. This approach enabled us to characterize the diverse cell populations involved in the liver metastatic process.Results: Our analysis revealed a significant involvement of fibroblasts and mural cells in AEGJ liver metastasis. We identified a specific fibroblast type in AEGJ liver metastasis and observed distinct gene expression patterns between adenocarcinoma of the esophagogastric junction and other stomach adenocarcinomas. Our study demonstrated high expression of the SFRP2 gene in pericyte cells during the liver metastasis of AEGJ. The incorporation of GEO, TCGA, and immunofluorescence staining of SFRP2 expression enhanced our study. High expression of SFRP2 in pericytes may influence vascular stability and angiogenesis through the Wnt pathway.Conclusion: Our study provides novel insights into the cellular interactions and molecular mechanisms that underlie AEGJ liver metastasis. Targeting the identified subtype of fibroblasts or influencing SFRP2 gene expression in pericytes may offer new therapeutic strategies for combating this aggressive tumor.
- Open Access
- 4 November 2024
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 480 (4) , 2633-2643
O-GlcNAcylation of hexokinase 2 modulates mitochondrial dynamics and enhances the progression of lung cancer
Non-small cell lung cancer (NSCLC) stands as the prevailing manifestation of lung cancer, with current therapeutic modalities linked to a dismal prognosis, necessitating further advancements. Hexokinase 2 (HK2), a critical enzyme positioned on the mitochondrial membrane, exerts control over diverse biological pathways, thereby regulating cancer. Nevertheless, the precise role and mechanism of HK2 in NSCLC remain inadequately elucidated, warranting comprehensive investigation. HK2 expression in NSCLC tissues and cell lines was detected through immunohistochemistry and western blot analysis. Concurrently, shRNA assays were applied to scrutinize the impact of HK2 on cell proliferation, apoptosis, migration, and invasion processes in NSCLC cell lines, utilizing CCK8, flow cytometry, wound-healing assay, and transwell techniques. The involvement of HK2 in mitochondrial dynamics was probed through western blot analysis, mitochondrial membrane potential assay, and assessment of ROS generation. Next, the functional role of HK2 was assessed by examining its influence on xenograft tumor growth in nude mice in vivo. Further research has demonstrated that HK2 played a role in NSCLC through its O-GlcNAcylation process. The results of the study revealed that HK2 O-GlcNAcylation promoted the proliferation, migration, and invasive characteristics of NSCLC cells, while alleviating mitochondrial damage, whereas O-GlcNAcylation inactivation yielded the opposite effect. Furthermore, in vivo experiments in nude mice illustrated that HK2 O-GlcNAcylation could stimulate tumor growth in NSCLC. These results suggested that HK2 may impact mitochondrial dynamics in NSCLC through its O-GlcNAcylation, thereby contributing to the progression of NSCLC.
- 4 November 2024
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 480 (4) , 2633-2643
Open AccessO-GlcNAcylation of hexokinase 2 modulates mitochondrial dynamics and enhances the progression of lung cancer
Non-small cell lung cancer (NSCLC) stands as the prevailing manifestation of lung cancer, with current therapeutic modalities linked to a dismal prognosis, necessitating further advancements. Hexokinase 2 (HK2), a critical enzyme positioned on the mitochondrial membrane, exerts control over diverse biological pathways, thereby regulating cancer. Nevertheless, the precise role and mechanism of HK2 in NSCLC remain inadequately elucidated, warranting comprehensive investigation. HK2 expression in NSCLC tissues and cell lines was detected through immunohistochemistry and western blot analysis. Concurrently, shRNA assays were applied to scrutinize the impact of HK2 on cell proliferation, apoptosis, migration, and invasion processes in NSCLC cell lines, utilizing CCK8, flow cytometry, wound-healing assay, and transwell techniques. The involvement of HK2 in mitochondrial dynamics was probed through western blot analysis, mitochondrial membrane potential assay, and assessment of ROS generation. Next, the functional role of HK2 was assessed by examining its influence on xenograft tumor growth in nude mice in vivo. Further research has demonstrated that HK2 played a role in NSCLC through its O-GlcNAcylation process. The results of the study revealed that HK2 O-GlcNAcylation promoted the proliferation, migration, and invasive characteristics of NSCLC cells, while alleviating mitochondrial damage, whereas O-GlcNAcylation inactivation yielded the opposite effect. Furthermore, in vivo experiments in nude mice illustrated that HK2 O-GlcNAcylation could stimulate tumor growth in NSCLC. These results suggested that HK2 may impact mitochondrial dynamics in NSCLC through its O-GlcNAcylation, thereby contributing to the progression of NSCLC.
- 21 September 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 142 (Pt B) , 113224
Human decidual mesenchymal stem cells obtained from early pregnancy attenuate bleomycin-induced lung fibrosis by inhibiting inflammation and apoptosis
- 21 September 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 142 (Pt B) , 113224
Human decidual mesenchymal stem cells obtained from early pregnancy attenuate bleomycin-induced lung fibrosis by inhibiting inflammation and apoptosis
- Open Access
- 1 May 2024
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 16 (5) , 3317-3324
Comparative outcomes of video-assisted thoracoscopic surgery versus open surgery for bronchogenic cysts in adults: a retrospective cohort study
Background: Open thoracotomy has been the traditional surgical approach for patients with bronchogenic cysts (BCs). This study aimed to evaluate the safety and efficacy of video-assisted thoracoscopic surgery (VATS) compared to open surgery for the treatment of BCs in adults. Methods: This single-institution, retrospective cohort study included 117 consecutive adult patients who underwent VATS (group A) or open surgery (group B) for BC resection between February 2019 and January 2023. Data regarding clinical history, operation duration, length of hospital stay, 30-day mortality, and recurrence during follow-up were collected and analyzed. Results: Of the total cohort, 103 (88.0%) patients underwent VATS, while 14 (12.0%) patients underwent open surgery. Patients’ age in group B were much older than group A (P=0.014), and no significant differences in other demographic and baseline clinical characteristics were observed between the groups. The VATS group had shorter median operation duration (96 vs. 149.5 min, Pvs. 8.6±4.0 days, PConclusions: Compared to open surgery, VATS is also a safe and efficacious approach for treating BCs in adults. What’s more, VATS offered shorter operative times and hospital stays. Considering the minimally invasive, VATS may be a better choice in most patients with bronchial cysts.
- 1 May 2024
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 16 (5) , 3317-3324
Open AccessComparative outcomes of video-assisted thoracoscopic surgery versus open surgery for bronchogenic cysts in adults: a retrospective cohort study
Background: Open thoracotomy has been the traditional surgical approach for patients with bronchogenic cysts (BCs). This study aimed to evaluate the safety and efficacy of video-assisted thoracoscopic surgery (VATS) compared to open surgery for the treatment of BCs in adults. Methods: This single-institution, retrospective cohort study included 117 consecutive adult patients who underwent VATS (group A) or open surgery (group B) for BC resection between February 2019 and January 2023. Data regarding clinical history, operation duration, length of hospital stay, 30-day mortality, and recurrence during follow-up were collected and analyzed. Results: Of the total cohort, 103 (88.0%) patients underwent VATS, while 14 (12.0%) patients underwent open surgery. Patients’ age in group B were much older than group A (P=0.014), and no significant differences in other demographic and baseline clinical characteristics were observed between the groups. The VATS group had shorter median operation duration (96 vs. 149.5 min, Pvs. 8.6±4.0 days, PConclusions: Compared to open surgery, VATS is also a safe and efficacious approach for treating BCs in adults. What’s more, VATS offered shorter operative times and hospital stays. Considering the minimally invasive, VATS may be a better choice in most patients with bronchial cysts.
- Open Access
- 24 April 2024
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Oncology
- Vol. 15 (4) , 554-565
Regulation of TMEM100 expression by epigenetic modification, effects on proliferation and invasion of esophageal squamous carcinoma
Regulation of TMEM100 expression by epigenetic modification, effects on proliferation and invasion of esophageal squamous carcinoma
- 24 April 2024
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Oncology
- Vol. 15 (4) , 554-565
Open AccessRegulation of TMEM100 expression by epigenetic modification, effects on proliferation and invasion of esophageal squamous carcinoma
Regulation of TMEM100 expression by epigenetic modification, effects on proliferation and invasion of esophageal squamous carcinoma
- Open Access
- 24 February 2024
- Published by Springer Nature in Cancer Cell International
- Vol. 24 (1) , 1-14
ACADL-YAP axis activity in non-small cell lung cancer carcinogenicity
Background: The role of Acyl-CoA dehydrogenase long chain (ACADL) in different tumor types had different inhibiting or promoting effect. However, its role in non-small cell lung cancer (NSCLC) carcinogenicity is not clear. Method: In this study, we utilized The Cancer Genome Atlas (TCGA) database to analyze ACADL expression in NSCLC and its correlation with overall survival. Furthermore, we investigated the function of ACADL on cellular proliferation, invasion, colony, apoptosis, cell cycle in vitro with NSCLC cells. Mechanistically, we evaluated the regulatory effect of ACADL expression on its downstream factor yes-associated protein (YAP) by assessing YAP phosphorylation levels and its cellular localization. Finally, we verified the tumorigenic effect of ACADL on NSCLC cells through xenograft experiments in vivo. Results: Compared to adjacent non-cancerous samples, ACADL significantly down-regulated in NSCLC. Overexpression of ACADL, effectively reduced the proliferative, colony, and invasive capabilities of NSCLC cells, while promoting apoptosis and inducing cell cycle arrest. Moreover, ACADL overexpression significantly enhanced YAP phosphorylation and hindered its nuclear translocation. However, the inhibitory effect of the overexpression of ACADL in NSCLC cells mentioned above can be partially counteracted by YAP activator XMU-MP-1 application both in vitro and in vivo. Conclusion: The findings suggest that ACADL overexpression could suppress NSCLC development by modulating YAP phosphorylation and limiting its nuclear shift. This role of ACADL-YAP axis provided novel insights into NSCLC carcinogenicity and potential therapeutic strategies.
- 24 February 2024
- Published by Springer Nature in Cancer Cell International
- Vol. 24 (1) , 1-14
Open AccessACADL-YAP axis activity in non-small cell lung cancer carcinogenicity
Background: The role of Acyl-CoA dehydrogenase long chain (ACADL) in different tumor types had different inhibiting or promoting effect. However, its role in non-small cell lung cancer (NSCLC) carcinogenicity is not clear. Method: In this study, we utilized The Cancer Genome Atlas (TCGA) database to analyze ACADL expression in NSCLC and its correlation with overall survival. Furthermore, we investigated the function of ACADL on cellular proliferation, invasion, colony, apoptosis, cell cycle in vitro with NSCLC cells. Mechanistically, we evaluated the regulatory effect of ACADL expression on its downstream factor yes-associated protein (YAP) by assessing YAP phosphorylation levels and its cellular localization. Finally, we verified the tumorigenic effect of ACADL on NSCLC cells through xenograft experiments in vivo. Results: Compared to adjacent non-cancerous samples, ACADL significantly down-regulated in NSCLC. Overexpression of ACADL, effectively reduced the proliferative, colony, and invasive capabilities of NSCLC cells, while promoting apoptosis and inducing cell cycle arrest. Moreover, ACADL overexpression significantly enhanced YAP phosphorylation and hindered its nuclear translocation. However, the inhibitory effect of the overexpression of ACADL in NSCLC cells mentioned above can be partially counteracted by YAP activator XMU-MP-1 application both in vitro and in vivo. Conclusion: The findings suggest that ACADL overexpression could suppress NSCLC development by modulating YAP phosphorylation and limiting its nuclear shift. This role of ACADL-YAP axis provided novel insights into NSCLC carcinogenicity and potential therapeutic strategies.